Aclaris Therapeutics, Inc. (ACRS): Total Liabilities
$57.38M
As of 2025-12-31
$55.11M
As of 2026-06-30
+0.2%
3-year compound annual growth
+11.6%
5-year compound annual growth
+43.5%
10-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $57.38M | -11.4% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $64.77M | +61.0% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $40.23M | -29.4% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $56.98M | +5.8% | 2024-02-27, Balance as of period end |
| 2021-12-31 | $53.87M | +62.6% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $33.13M | +16.7% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $28.39M | -53.0% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $60.44M | +231.2% | 2020-02-25, Balance as of period end |
| 2017-12-31 | $18.25M | +176.7% | 2019-03-18, Balance as of period end |
| 2016-12-31 | $6.59M | +324.1% | 2018-03-12, Balance as of period end |
| 2015-12-31 | $1.55M | +6.9% | 2017-03-15, Balance as of period end |
| 2014-12-31 | $1.46M | n/a | 2016-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $57.38M | -11.4% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $6.92M | +45.1% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $30.24M | -28.7% |
| Adagene Inc. (ADAG) | 2025-12-31 | $26.36M | -32.0% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $51.40M | +18.9% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $416.27M | +66.7% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $20.27M | -15.3% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $14.52M | -18.6% |
| Immunome Inc. (IMNM) | 2025-12-31 | $48.84M | -17.3% |
Compare ACRS, COYA, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗